Regeneron
Lynozyfic
page 4 of 6
4C
(near Multiple 
Myeleoma)
© 2026 Regeneron Pharmaceuticals, Inc. All rights reserved.
777 Old Saw Mill River Road, Tarrytown, NY 10591
US.LYN.26.02.0014   04/26
IMPORTANT SAFETY INFORMATION (cont’d)
Warnings and Precautions (cont’d)
Neutropenia: LYNOZYFIC can cause neutropenia and febrile neutropenia. In patients who received 
LYNOZYFIC at the recommended dose in LINKER-MM1, decreased neutrophil count occurred in 62%  
of patients with Grade 3 or 4 decreased neutrophil count in 47%. Febrile neutropenia occurred in 8%  
of patients.
Monitor complete blood cell counts at baseline and periodically during treatment and provide 
supportive care per local guidelines. Monitor patients with neutropenia for signs of infection. Withhold 
LYNOZYFIC based on severity.
Hepatotoxicity: LYNOZYFIC can cause hepatotoxicity. In LINKER-MM1, elevated ALT occurred in 46% 
of patients, with Grade 3 or 4 ALT elevation occurring in 6%; elevated AST occurred in 61% of patients, 
with Grade 3 or 4 AST elevation occurring in 10% of patients who received the recommended dose. 
Grade 3 or 4 total bilirubin elevations occurred in 1.7% of patients. Liver enzyme elevation can occur 
with or without concurrent CRS.
Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold 
LYNOZYFIC or consider permanent discontinuation of LYNOZYFIC based on severity.
Embryo-Fetal Toxicity: Based on its mechanism of action, LYNOZYFIC may cause fetal harm when 
administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise 
females of reproductive potential to use effective contraception during treatment with LYNOZYFIC 
and for 3 months after the last dose.
Adverse Reactions
The most common adverse reactions (≥20%) are musculoskeletal pain, cytokine release syndrome, 
cough, upper respiratory tract infection, diarrhea, fatigue, pneumonia, nausea, headache, and dyspnea. 
The most common Grade 3 or 4 laboratory abnormalities (≥30%) are decreased lymphocyte count, 
decreased neutrophil count, decreased hemoglobin, and decreased white blood cell count. 
Use in Specific Populations
Lactation: Advise not to breastfeed.
Please see Brief Summary of Prescribing Information, including Boxed WARNING, for LYNOZYFIC on 
the following pages.

View this content as a flipbook by clicking here.